Perrigo (PRGO) Depreciation & Amortization (CF) (2013 - 2026)
Perrigo's (PRGO) quarterly Depreciation & Amortization (CF) came in at $83.3 million in Q1 2026, up 4.26% year-on-year from $79.9 million in Q1 2025, and down 3.03% on a QoQ basis from $85.9 million in Q4 2025.
Perrigo (PRGO) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $83.3 million in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) rose 4.26% year-over-year to $83.3 million in Q1 2026; TTM through Mar 2026 was $340.9 million, a 5.09% increase from a year earlier, with the FY2025 full-year figure at $337.5 million, up 3.56% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $83.3 million, down from $85.9 million in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for PRGO reached as high as $97.1 million in Q4 2022 and fell as low as $69.5 million in Q2 2022.
- Historically, Depreciation & Amortization (CF) has averaged $85.0 million across 5 years, with a median of $85.4 million in 2025.
- On a YoY basis, Depreciation & Amortization (CF) climbed as much as 32.29% in 2022 and fell as far as 23.12% in 2022.
- Year by year, Depreciation & Amortization (CF) stood at $97.1 million in 2022, then dropped by 11.53% to $85.9 million in 2023, then dropped by 6.52% to $80.3 million in 2024, then rose by 6.97% to $85.9 million in 2025, then slipped by 3.03% to $83.3 million in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $83.3 million in Q1 2026, $85.9 million in Q4 2025, and $85.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn | 83.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 83.30 Mn |
| Mar 28, 2026 | 83.30 Mn |
| Dec 31, 2025 | 85.90 Mn |
| Dec 31, 2025 | 85.90 Mn |
| Sep 27, 2025 | 85.40 Mn |
| Sep 27, 2025 | 85.40 Mn |
| Jun 28, 2025 | 86.30 Mn |
| Jun 28, 2025 | 86.30 Mn |
| Mar 29, 2025 | 79.90 Mn |
| Mar 29, 2025 | 79.90 Mn |
| Dec 31, 2024 | 80.30 Mn |
| Dec 31, 2024 | 80.30 Mn |
| Sep 28, 2024 | 82.30 Mn |
| Sep 28, 2024 | 82.30 Mn |
| Jun 29, 2024 | 81.90 Mn |
| Jun 29, 2024 | 81.90 Mn |
| Mar 30, 2024 | 81.40 Mn |
| Mar 30, 2024 | 81.40 Mn |
| Dec 31, 2023 | 85.90 Mn |
| Dec 31, 2023 | 85.90 Mn |